Shots:

• Five-year data from P-III MURANO trial shows sustained PFS with Venclexta/Venclyxto + MabThera/Rituxan vs BR in patients with r/r CLL
• The data showed a reduction in the risk of disease progression or death by 81%- m-OS (82.1% vs 62.2%)- patients who completed 2yrs. of treatment without the progressive disease- 63.8% had uMRD
• The P-III CLL14 study also confirms the potential of MRD measurements to predict future outcomes for people with prior untreated CLL who were treated with fixed-duration Venclexta/Venclyxto + Gazyva/Gazyvaro vs Gazyva/Gazyvaro + chlorambucil

 ­ Ref: Roche | Image: Roche